A Study of 7MW3711 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1/2 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06008379
• Other study ID #: 7MW3711-2023-CP102
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 28, 2023
• Est. completion date: January 30, 2026

Study information

• Verified date: September 2023
• Source: Mabwell (Shanghai) Bioscience Co., Ltd.
• Contact: Sun Lu, Doctor
• Phone: 021-22200000*3121
• Email: shun-lu[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

7MW3711 is a antibody-drug conjugate(ADC) drected to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in subjects with advanced solid tumors.

Description:

Two parts are included in this study. The part of dose escalation and dose expansion(part 1) will enrolled subjects with advanced solid tumors and is to evaluate the safety and tolerability and to determine the maximum tolerated dose and/or the recommend pahse 2 dose(RP2D) of 7MW3711 in subjects with advanced solid tumors.

The part of cohort expansion(part 2) will enrolled subejcts with selected advanced solid tumors and is to assess the preliminary efficacy of 7MW3711 in selected advanced solid tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 164
• Est. completion date: January 30, 2026
• Est. primary completion date: August 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

• Life expectancy of at least 3 months as assessed by the Investigator.

• Part 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment received and who progressed on or after standard therapies or intolerant to approved therapies or who lack of effient standard therapies; part 2: Histologically or cytologically confirmed locally advanced or metastatic selected advanced solid tumors having progressed after at least one line of standard systermic therapy or intolerate standard therapies.

• An archival tumor tissue sample(formalin-fixed paraffin-embedded (FFPE) tumor tissue block or at least 5 unstained slides) or a fresh tissue sample should be provided. If the tissue sample cannot be provided during dose escalation, enrollment into the study is allowed after discussion with the Investigator

• Measurable or evaluable disease by RECIST v1.1.

• Have adequate hematopoietic, renal and hepatic functions.

• Men or women willing to use adequate contraceptive measures throughout the study

Exclusion Criteria:

• Have other prior malignancies within 3 years before the first administration.

• Known central nervous system metastatic disease or carcinomatous meningitis except for treated and stable brain metastases.

• Have significant, uncontrolled, or active cardiovascular disease.

• Known history of COPD, or intestinal lung disease, or other respiratory diseases requring inpatient treatments within 4 weeks prior to first administration.

• Have adverse events due to prior antitumor therapy not resolved to grade 1 or lower by NCI CTCAE V5.0.

• have active infections requiring treatment within 14 weeks; have infection of HIV, active infection of HCV and HBV.

• Prior treatment with an antibody drug conjugate (ADC) that consists of an topoisomerase I inhibitor.

• Prior treatment with B7-H3 targeted agents.

• have received chemotherapy, immunotherapy, curative radiation within 3 weeks prior to the first administration or targeted molecular within 2 weeks prior to first administration. have received Chinese patent medicine or Chinese herbs of anti-tumor indications within 1 weeks prior to the first administration.

• Have received any systemic immunosuppressants within 2 weeks prior to the first administration except for topical corticosteroids.

• Have received any other investigational drugs or medical device within 4 weeks prior to the first administration.

• History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening.

• Pregnant, or nursing females

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• 7MW3711 for injection
IV administration of 7MW3711, Q3W, 3 weeks a cycle
• 7MW3711 for injection
IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1

Locations

Country	Name	City	State
China	Hunan Cancer Hospital	Changsha	Hunan
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang
China	The Lung Cancer Center of Shanghai Chest Hospital	Shanghai	Shanghai
China	Xuzhou Central Hospital	Xuzhou	Jiangsu
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Mabwell (Shanghai) Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluation of the incidence of adverse events (AEs) (part 1)	Incidence and seriousness of adverse events (AEs) and serious adverse events (SAEs) by CTCAE version 5.0.	approximately up to 16 cycles, 21 days a cycle
Primary	Identification of the MTD and /or RP2D of 7MW3711(part 1)		from Day1 to Day21 in cycle1 of part 1
Primary	Overall response rate (ORR) evaluated by investigators based on RECIST version 1.1 in selected solid tumors. (part 2)	ORR:defined as the proportion of patients who achieved a best overall response of completeresponse (CR) or partial response (PR)	approximately up to 2 years
Secondary	evaluation of PK parameters of 7MW3711	Maximum observed concentration(Cmax)	approximately up to 2 years
Secondary	evaluation of PK parameters of 7MW3711	the time to Cmax(tmax)	approximately up to 2 years
Secondary	evaluation of PK parameters of 7MW3711	half-live(t1/2)	approximately up to 2 years
Secondary	evaluation of PK parameters of 7MW3711	Area under the concentration-time curve(AUC)	approximately up to 2 years
Secondary	overall response rate (ORR) (part1)	ORR:defined as the proportion of patients who achieved a best overall response of completeresponse (CR) or partial response (PR) based on RECIST version 1.1.	approximately up to 1 years
Secondary	disease control rate(DCR)	DCR:defined as the proportion of subjects with CR, PR, and SD based on RECIST 1.1 criteria	approximately up to 2 years
Secondary	progression-free survival(PFS)	PFS:defined as time from the date of first administration to the date of first documented disease progression based on RECIST 1.1 criteria, or death due to any cause, whichever occurs first	approximately up to 2 years
Secondary	time to response (TTR)	TTR:defined as time from the date of first administration to the date of first documented CR or PR	approximately up to 2 years
Secondary	evaluation of the immunogenicity of 7MW3711	Frequency and percentage of subjects with positive anti-drug antibody after being treated by 7MW3711.	approximately up to 2 years
Secondary	evaluation of the incidence of adverse events (AEs) (part 2)	Incidence and seriousness of adverse events (AEs) and serious adverse events (SAEs) by CTCAE version 5.0.	approximately up to 2 years